Table 2.
Baseline characteristics
| Subject’s characteristics | No. of subjects (%) (n = 1134) |
| Age (years) | 62.7±13.8 |
| Tumor stage | |
| I | 639 (56.4) |
| II | 408 (36.0) |
| III | 87 (7.7) |
| Cancer type | |
| Ductal | 824 (72.7) |
| Lobular | 137 (12.1) |
| Ductal and lobular | 81 (7.1) |
| Inflammatory | 15 (1.3) |
| Others | 77 (6.8) |
| Histologic grade | |
| Well differentiated | 240 (21.2) |
| Moderately differentiated | 435 (38.4) |
| Poorly differentiated | 407 (35.9) |
| Missing | 52 (4.6) |
| Tumor size | |
| ≤2 cm | 810 (71.4) |
| 2.1 to 5 cm | 262 (23.1) |
| >5 cm | 53 (4.7) |
| Missing | 9 (0.8) |
| Lymph node status | |
| Positive | 351 (31.0) |
| Negative | 694 (61.2) |
| Not examined | 89 (7.8) |
| Tumor subtypes | |
| ER status positive | 883 (77.9) |
| ER status negative | 251 (22.1) |
| PR status positive | 670 (59.1) |
| PR status negative | 464 (40.9) |
| Her2 status positive | 201 (17.7) |
| Her2 status negative | 933 (82.3) |
| ER/PR+, Her2+ | 116 (10.2) |
| ER/PR+, Her2− | 781 (68.9) |
| ER/PR−, Her2+ | 85 (7.5) |
| ER/PR−, Her2− | 152 (13.4) |
| Surgery | |
| No surgery | 17 (1.5) |
| Surgery | 1117 (98.5) |
| Chemotherapy | 519 (45.8) |
| Radiotherapy | 736 (64.9) |
| Hormone replacement therapy | 792 (69.8) |
ER = estrogen receptor, Her2 = human epidermal growth factor receptor 2, PR = progesterone receptor, + = positive, − = negative.